Ser30
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser30  -  LUZP5 (human)

Site Information
VQLDKEAsDPFSLNE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4270687

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:
cervical cancer ( 4 ) , cervical adenocarcinoma ( 4 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 1 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 2 ) , HeLa S3 (cervical) ( 2 , 4 , 5 ) , HeLa_Meta (cervical) ( 3 ) , HeLa_Pro (cervical) ( 3 ) , HeLa_Telo (cervical) ( 3 )

Upstream Regulation
Regulatory protein:
PLK1 (human) ( 2 )
Treatments:
MG132_withdrawal ( 3 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

3

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

4

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

5

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info